The Alliance for Artificial Intelligence in Healthcare (AAIH)’s Post

🔍 How can we leverage single-cell multi-omics, functional assays, and machine learning to better characterize diseases and develop transformational medicines? On today's episode of the AWS Health Innovation Podcast, Yin He welcomes Lindsay Edwards to the show, the CTO and President of Platform at Relation. Lindsay will share his insights on their unique approach to drug discovery, his unconventional career path from musician to drug hunter, and the company's focus on using single-cell data to find better drug targets. Tune in to learn about: 🦠 Relation's unconventional approach to drug discovery, leveraging human biological insights and single-cell data to pinpoint high potential drug targets. 🔬 How Relation integrates lab experiments and machine learning through their "Lab-in-the-Loop" approach. 💊 The company's focus on developing precision medicines for osteoporosis, studying osteoblasts and genetic determinants of bone density. ... and so much more 🔉 Listen on the Health Podcast Network, or wherever you listen to your podcasts: https://lnkd.in/dGyBf3fG Learn more about: ➡️ Relation: https://lnkd.in/dXyx3-cc ➡️ How healthcare & life sciences industry leaders leverage the cloud to accelerate health innovation: https://lnkd.in/dBRBKptV #AWSHealthPod #HealthcarePodcasts #Biotech #PrecisionMedicine

Drug discovery takes on average: ⏱️ 12-15 years to make an impact to patients 💲 USD 1-3 Billion 😲 failure rate of 85-90% - only 10-15% make it to the market On this podcast you will find out how some innovators are trying to change that.

🔬 Explore the Future of Drug Discovery! Join our expert panel as we dive into how AI/ML and patient data are revolutionizing the fight against complex diseases. Hear from leading experts in biotech, genomics, and neuroscience about their latest breakthroughs and innovations. 🌟 Register NOW to secure your spot! #AI #ML #DrugDiscovery #Biotech #Genomics #Neuroscience #WIBSF

🔍 How can we leverage single-cell multi-omics, functional assays, and machine learning to better characterize diseases and develop transformational medicines? On today's episode of the AWS Health Innovation Podcast, Yin He welcomes Lindsay Edwards to the show, the CTO and President of Platform at Relation. Lindsay will share his insights on their unique approach to drug discovery, his unconventional career path from musician to drug hunter, and the company's focus on using single-cell data to find better drug targets. Tune in to learn about: 🦠 Relation's unconventional approach to drug discovery, leveraging human biological insights and single-cell data to pinpoint high potential drug targets. 🔬 How Relation integrates lab experiments and machine learning through their "Lab-in-the-Loop" approach. 💊 The company's focus on developing precision medicines for osteoporosis, studying osteoblasts and genetic determinants of bone density. ... and so much more 🔉 Listen on the Health Podcast Network, or wherever you listen to your podcasts: https://lnkd.in/en5BgJSB Learn more about: ➡️ Relation: https://lnkd.in/emN2z2X2 ➡️ How healthcare & life sciences industry leaders leverage the cloud to accelerate health innovation: https://lnkd.in/eW3GGqc5 #AWSHealthPod #HealthcarePodcasts #Biotech #PrecisionMedicine Abhijit Kulkarni Tricia Troth Mariel K Rossi Adam McCarthy Jake P. Taylor-King

Newest episode from stats biotech news

Our CMO, David Dimmock, spoke with CGTLive about our work using AI to engineer an antisense oligonucleotide (ASO) therapeutic. We engineered an allele-selective oligonucleotide-based medicine for a patient with an ultra-rare disease. Our proprietary AI platform accelerated the ASO design process, allowing for swift progress from concept to treatment. The patient received their first dose about one year after project initiation - so far it's been exceptionally well tolerated and we're excited by the benefit the drug seems to be providing. Want to hear more? Check out part 1 of the interview here: https://lnkd.in/e_WD45ui #RareDiseases #AI #PersonalizedMedicine #CreyonBio #ASGCT2024 #Biotechnology

Check out Kennedy Schaal 's fascinating talk about the innovative work happening at Rejuve.Bio They are making waves in longevity therapeutics by focusing on:  ✔️Building a biomedical research platform ✔️Creating science-backed longevity therapeutics ✔️Collaborating with pharmaceutical companies for drug discovery AI's Role: By integrating AI, long-lived animal models, and crowdsourced human data, Rejuve Bio is paving the way for groundbreaking solutions in healthspan optimization. Addressing Bias: Kennedy emphasizes the importance of democratizing biomedical research and ensuring diverse data representation to improve healthcare outcomes for everyone. Looking Ahead: With hopes for significant breakthroughs in longevity research within the next year, Kennedy's work is set to make a real impact on preventative medicine. Interested in learning more? Check out the full talk here: https://lnkd.in/d6GhY-GK #Longevity #HealthTech #RejuveBio #Innovation #PreventativeMedicine #AI #Biotech #LSD2024

Introducing our Day One Keynote with Bari Kowal from Regeneron at the #FierceClinicalSummit ✨ What you can expect at this session: 🔹Examine the impact of adapting and modernizing trial design and protocols to drive efficiencies 🔹Evaluate the utilization of digital health technologies, digital biomarkers, and real-world evidence to enhance clinical data collection 🔹Consider the role of AI in clinical development and how to harness it for optimal results 🔹Discuss the promise of genetic medicines and what it means for the future of clinical trials Register Now: https://ow.ly/oPZP50SNz1U #WeAreFierce #FiercePharma #FierceBiotech #ClinicalResearch #ClinicalTrials #ClinicalOperations #ClinicalQuality #ClinicalData

Our CEO, Dr Joerg Moeller, M.D., shares his expertise on the real-world value of generative AI as part of WSJ CEO Council: “The pharma and biotech industry still faces over a 90% failure rate in drug development, and 9,000 diseases lack effective treatments.  By integrating data from a vast range of sources—from genetics to clinical trials across all disease areas—generative AI can help us uncover new insights, identify new drug targets and improve success rates while reducing timelines. Patient-driven disease modelling focuses on mechanisms driving tailored medicines, while AI’s agnostic approach helps us overcome challenges even top scientists face.” The feature is available in the print edition of The Wall Street Journal, alongside insights from: 👉 Ken Keller of Daiichi Sankyo US   👉 Brian Becker of RSM US LLP 👉 Revathi Advaithi of Flex #WSJCEOCouncil #CEOExcellence

In this article, Rolf Turk from Integrated DNA Technologies discusses the future of CRISPR and the opportunity to develop new tools for genomic medicine.